Advanced search
Publication Cover
Xenobiotica
the fate of foreign compounds in biological systems
Volume 31, 2001 - Issue 8-9
Submit an article Journal homepage
117
Views
35
CrossRef citations to date
0
Altmetric
Research Article

Potential role for P-glycoprotein in the nonproportional pharmacokinetics of UK-343,664 in man

S. Abel Department of Drug Metabolism and Clinical Sciences, Pfizer Global Research and Development, Sandwich CT13 9NJ, UK
,
K. C. Beaumont Department of Drug Metabolism and Clinical Sciences, Pfizer Global Research and Development, Sandwich CT13 9NJ, UK
,
C. L. Crespi Department of Drug Metabolism and Clinical Sciences, Pfizer Global Research and Development, Sandwich CT13 9NJ, UK
,
M. D. Eva Department of Drug Metabolism and Clinical Sciences, Pfizer Global Research and Development, Sandwich CT13 9NJ, UK
,
L. Fox Department of Drug Metabolism and Clinical Sciences, Pfizer Global Research and Development, Sandwich CT13 9NJ, UK
,
R. Hyland Department of Drug Metabolism and Clinical Sciences, Pfizer Global Research and Development, Sandwich CT13 9NJ, UK
,
B. C. Jones Department of Drug Metabolism and Clinical Sciences, Pfizer Global Research and Development, Sandwich CT13 9NJ, UK
,
G. J. Muirhead Department of Drug Metabolism and Clinical Sciences, Pfizer Global Research and Development, Sandwich CT13 9NJ, UK
,
D. A. Smith Department of Drug Metabolism and Clinical Sciences, Pfizer Global Research and Development, Sandwich CT13 9NJ, UK
,
R. F. Venn Department of Drug Metabolism and Clinical Sciences, Pfizer Global Research and Development, Sandwich CT13 9NJ, UK
&
D. K. Walker Department of Drug Metabolism and Clinical Sciences, Pfizer Global Research and Development, Sandwich CT13 9NJ, UK
 show all
Pages 665-676 | Published online: 22 Sep 2008

Citations (35)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (5)

Susan Hurst, Cho-Ming Loi, Joanne Brodfuehrer & Ayman El-Kattan. (2007) Impact of physiological, physicochemical and biopharmaceutical factors in absorption and metabolism mechanisms on the drug oral bioavailability of rats and humans. Expert Opinion on Drug Metabolism & Toxicology 3:4, pages 469-489.
Read now
V Hayden Thomas, Shobha Bhattachar, Linda Hitchingham, Philip Zocharski, Maryanne Naath, Narayanan Surendran, Chad L Stoner & Ayman El-Kattan. (2006) The road map to oral bioavailability: an industrial perspective. Expert Opinion on Drug Metabolism & Toxicology 2:4, pages 591-608.
Read now
Zhihua Sui. (2003) Phosphodiesterase-5 inhibitors for male erectile dysfunction. Expert Opinion on Therapeutic Patents 13:9, pages 1373-1388.
Read now
A. Ayrton & P. Morgan. (2001) Role of transport proteins in drug absorption, distribution and excretion. Xenobiotica 31:8-9, pages 469-497.
Read now
D. K. Walker, K. C. Beaumont, P. Comby, K. M. Evans, J. I. Gedge, R. C. Halliday, S. J. Roffey & P. A. Wright. (2001) Pharmacokinetics and metabolism of a selective PDE5 inhibitor (UK-343,664) in rat and dog. Xenobiotica 31:8-9, pages 651-664.
Read now

Articles from other publishers (30)

Ayman El‐Kattan. 2023. Oral Bioavailability and Drug Delivery. Oral Bioavailability and Drug Delivery 677 700 .
Terry P. Kenakin. 2022. A Pharmacology Primer. A Pharmacology Primer 307 357 .
Thomas Straubinger, Katherine Kay & Robert Bies. (2020) Modeling HIV Pre-Exposure Prophylaxis. Frontiers in Pharmacology 10.
Crossref
Tohru Miyazaki, Masanori Kawasaki, Atsushi Suzuki, Yuki Ito, Akio Imanishi, Takamitsu Maru, Tomohiro Kawamoto & Tatsuki Koike. (2019) Discovery of novel 4-phenyl-2-(pyrrolidinyl)nicotinamide derivatives as potent Nav1.1 activators. Bioorganic & Medicinal Chemistry Letters 29:6, pages 815-820.
Crossref
Terry P. Kenakin. 2019. A Pharmacology Primer. A Pharmacology Primer 245 293 .
Ryo Mizojiri, Daisuke Nakata, Yoshihiko Satoh, Daisuke Morishita, Sachio Shibata, Misa Iwatani-Yoshihara, Yohei Kosugi, Mai Kosaka, Junpei Takeda, Shigekazu Sasaki, Kazuaki Takami, Koichiro Fukuda, Masahiro Kamaura, Shinobu Sasaki, Ryosuke Arai, Douglas R. Cary & Yasuhiro Imaeda. (2017) Discovery of Novel 5-(Piperazine-1-carbonyl)pyridin-2(1 H )-one Derivatives as Orally eIF4A3-Selective Inhibitors . ACS Medicinal Chemistry Letters 8:10, pages 1077-1082.
Crossref
Ayman F. El‐Kattan. 2017. Oral Bioavailability Assessment. Oral Bioavailability Assessment 35 76 .
Li Di & Edward H. Kerns. 2016. Drug-Like Properties. Drug-Like Properties 463 470 .
Dafydd R. Owen. 2014. Phosphodiesterases and Their Inhibitors. Phosphodiesterases and Their Inhibitors 9 28 .
Terry P. Kenakin. 2014. A Pharmacology Primer. A Pharmacology Primer 213 253 .
Angela Dudda & Gert Ulrich Kuerzel. 2013. Drug Discovery and Evaluation: Safety and Pharmacokinetic Assays. Drug Discovery and Evaluation: Safety and Pharmacokinetic Assays 989 1004 .
Yan Li, Wenzhao Wu, Hong Ren, Jinghui Wang, Shuwei Zhang, Guohui Li & Ling Yang. (2012) Exploring the structure determinants of pyrazinone derivatives as PDE5 3HC8 inhibitors: An in silico analysis. Journal of Molecular Graphics and Modelling 38, pages 112-122.
Crossref
Olga A.H. Reneerkens, Kris Rutten, Sven Akkerman, Arjan Blokland, Christopher L. Shaffer, Frank S. Menniti, Harry W.M. Steinbusch & Jos Prickaerts. (2012) Phosphodiesterase type 5 (PDE5) inhibition improves object recognition memory: Indications for central and peripheral mechanisms. Neurobiology of Learning and Memory 97:4, pages 370-379.
Crossref
Bilal S. Abuasal, Michael B. Bolger, Don K. WalkerAmal Kaddoumi. (2012) In Silico Modeling for the Nonlinear Absorption Kinetics of UK-343,664: A P-gp and CYP3A4 Substrate . Molecular Pharmaceutics 9:3, pages 492-504.
Crossref
David J. Rawson, Stephen Ballard, Christopher Barber, Laura Barker, Kevin Beaumont, Mark Bunnage, Susan Cole, Martin Corless, Stephen Denton, David Ellis, Marion Floc’h, Laura Foster, James Gosset, Frances Holmwood, Charlotte Lane, David Leahy, John Mathias, Graham Maw, William Million, Cedric Poinsard, Jenny Price, Rachel Russel, Stephen Street & Lesa Watson. (2012) The discovery of UK-369003, a novel PDE5 inhibitor with the potential for oral bioavailability and dose-proportional pharmacokinetics. Bioorganic & Medicinal Chemistry 20:1, pages 498-509.
Crossref
Ayman El‐Kattan, Susan Hurst, Joanne Brodfuehrer & Cho‐Ming Loi. 2011. Oral Bioavailability. Oral Bioavailability 253 265 .
Barry Weatherley & Lynn McFadyen. (2009) Maraviroc modelling strategy: use of early phase 1 data to support a semi‐mechanistic population pharmacokinetic model. British Journal of Clinical Pharmacology 68:3, pages 355-369.
Crossref
Mark E. Bunnage, John P. Mathias, Anthony Wood, Duncan Miller & Stephen D.A. Street. (2008) Highly potent and selective chiral inhibitors of PDE5: An illustration of Pfeiffer’s rule. Bioorganic & Medicinal Chemistry Letters 18:23, pages 6033-6036.
Crossref
Guangqing Xiao & Charles L. Crespi. 2008. Drug Bioavailability. Drug Bioavailability 359 372 .
Samantha Abel, Elna Van Der Ryst, Maria C. Rosario, Caroline E. Ridgway, Christine G. Medhurst, Richard J. Taylor‐Worth & Gary J. Muirhead. (2008) Assessment of the pharmacokinetics, safety and tolerability of maraviroc, a novel CCR5 antagonist, in healthy volunteers. British Journal of Clinical Pharmacology 65:s1, pages 5-18.
Crossref
Dmitri Pissarnitski. (2005) Phosphodiesterase 5 (PDE 5) inhibitors for the treatment of male erectile disorder: Attaining selectivity versus PDE6. Medicinal Research Reviews 26:3, pages 369-395.
Crossref
Amal Kaddoumi, David Fleisher, Tycho Heimbach, Lilian Y. Li & Susan Cole. (2006) Factors influencing regional differences in intestinal absorption of UK-343,664 in rat: Possible role in dose-dependent pharmacokinetics. Journal of Pharmaceutical Sciences 95:2, pages 435-445.
Crossref
Angela Dudda & Gert Ulrich Kürzel. 2006. Drug Discovery and Evaluation. Drug Discovery and Evaluation 551 557 .
David T. Manallack, Richard A. Hughes & Philip E. Thompson. (2005) The Next Generation of Phosphodiesterase Inhibitors:  Structural Clues to Ligand and Substrate Selectivity of Phosphodiesterases. Journal of Medicinal Chemistry 48:10, pages 3449-3462.
Crossref
Don K. Walker, Samantha Abel, Pierre Comby, Gary J. Muirhead, Angus N. R. Nedderman & Dennis A. Smith. (2005) SPECIES DIFFERENCES IN THE DISPOSITION OF THE CCR5 ANTAGONIST, UK-427,857, A NEW POTENTIAL TREATMENT FOR HIV. Drug Metabolism and Disposition 33:4, pages 587-595.
Crossref
D. K. Walker. (2004) The use of pharmacokinetic and pharmacodynamic data in the assessment of drug safety in early drug development. British Journal of Clinical Pharmacology 58:6, pages 601-608.
Crossref
Anthony Harrison, Alison Betts, Katherine Fenner, Kevin Beaumont, Alan Edgington, Sarah Roffey, John Davis, Pierre Comby & Paul Morgan. (2004) NONLINEAR ORAL PHARMACOKINETICS OF THE α-ANTAGONIST 4-AMINO-5-(4-FLUOROPHENYL)-6,7-DIMETHOXY-2-[4-(MORPHOLINOCARBONYL)-PERHYDRO-1,4-DIAZEPIN-1-YL]QUINOLINE IN HUMANS: USE OF PRECLINICAL DATA TO RATIONALIZE CLINICAL OBSERVATIONS. Drug Metabolism and Disposition 32:2, pages 197-204.
Crossref
Toshihiro Wajima, Kazuya Fukumura, Yoshitaka Yano & Takayoshi Oguma. (2003) Prediction of Human Pharmacokinetics from Animal Data and Molecular Structural Parameters using Multivariate Regression Analysis: Oral Clearance. Journal of Pharmaceutical Sciences 92:12, pages 2427-2440.
Crossref
H. Spahn-Langguth, C. Dressler & C. Leisen. 2003. Stereochemical Aspects of Drug Action and Disposition. Stereochemical Aspects of Drug Action and Disposition 251 288 .
Andrew W Stamford. 2002. Annual Reports in Medicinal Chemistry Volume 37. Annual Reports in Medicinal Chemistry Volume 37 53 64 .

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.